HOBA
THERAPEUTICS

Developing Restorative Treatments for Pain, Hearing Loss, and Sensory Neuron Disorders

Our Company

Hoba Therapeutic is an early-stage biotech based in Denmark developing innovative treatments for chronic pain disorders and sensorineural hearing loss – indications with a high unmet medical need for safe and efficacious treatments for millions of patients worldwide.

Science

Our science is based on the discovery of a novel family of endogenous human proteins, meteorin and cometin. These are neurotrophic factors involved in the development, growth, survival, and maintenance of nerve cells, supporting glial cells and sensory pathways.

Our focus

Hoba Therapeutics holds the rights to two novel biopharmaceutical drugs

HB-086 is in late preclinical development for neuropathic pain. The target indications are CIPN and trigeminal neuralgia.

HB-097 is in preclinical development for sensorineural hearing loss. The target indication is ototoxic hearing loss.

blank

DISCOVER OUR MOVIE

Latest News

Hoba Therapeutics Appoints Jean Combalbert as Chairperson of the Board ofDirectors.

Copenhagen, March 1, 2024

Hoba Therapeutics, a Danish biotech company dedicated to developing novel therapeutic proteins for patients living ...

Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain

Copenhagen, December 11, 2023

Hoba Therapeutics, a Novo Holdings founded Danish biotech company dedicated to developing novel therapeutic ...

Eir Ventures invests in Hoba Therapeutics

Copenhagen, July 6, 2022

Hoba Therapeutics, a biotech company developing novel therapeutic proteins for pain, hearing loss, and sensory ...